Overview
Avi Kenny is an Assistant Professor in the Department of Biostatistics and Bioinformatics at Duke University, with a secondary appointment at the Duke Global Health Institute. He holds a PhD in biostatistics from the University of Washington, where he developed statistical methods for immune correlates analysis of vaccine clinical trial data. Prior to this, he worked for five years in Liberia as the Director of Research, Monitoring, and Evaluation at Last Mile Health. His current research interests include statistical methods to handle treatment effect heterogeneity in cluster randomized trials, survival analysis using machine learning tools, evaluation of global health programs, and data quality assurance in low-resource settings.
Current Appointments & Affiliations
Assistant Professor of Biostatistics & Bioinformatics
·
2024 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Assistant Research Professor of Global Health
·
2024 - Present
Duke Global Health Institute,
University Institutes and Centers
Recent Publications
Investigating Symptom Duration Using Current Status Data: A Case Study of Postacute COVID-19 Syndrome.
Journal Article Epidemiology · June 5, 2025 BACKGROUND: For infectious diseases, characterizing symptom duration is of clinical and public health importance. Symptom duration may be assessed by surveying infected individuals and querying symptom status at the time of survey response. For example, in ... Full text Link to item CiteFactors affecting power in stepped wedge trials when the treatment effect varies with time
Preprint · March 14, 2025 Link to item CiteImmune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.
Journal Article EBioMedicine · October 2024 BACKGROUND: The HVTN 705 Imbokodo trial of 2636 people without HIV and assigned female sex at birth, conducted in southern Africa, evaluated a heterologous HIV-1 vaccine regimen: mosaic adenovirus 26-based vaccine (Ad26.Mos4.HIV) at Months 0, 3, 6, 12 and ... Full text Link to item CiteRecent Grants
A randomized controlled trial of a novel, evidence-based algorithm for managing lower respiratory tract infection in a resource-limited setting
ResearchBiostatistician III · Awarded by National Institutes of Health · 2022 - 2027View All Grants
Education, Training & Certifications
University of Washington ·
2023
Ph.D.